Description:

The purpose of this guidance is to clarify the role of data integrity in current good manufacturing practice (CGMP) for drugs, as required in 21 CFR parts 210, 211, and 212. Unless otherwise noted, the term CGMP in this guidance refers to CGMPs for drugs (including biologics).This guidance provides the Agency’s current thinking on the creation and handling of data in accordance with CGMP requirements.

$0.00